STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone353-1232-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.78 billion
Profitability
Miscellaneous
Employees12,000
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Steris (NYSE:STE) Frequently Asked Questions
What is Steris' stock symbol?
Steris trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."
How often does Steris pay dividends? What is the dividend yield for Steris?
Steris announced a quarterly dividend on Monday, August 5th. Shareholders of record on Tuesday, September 10th will be given a dividend of $0.37 per share on Thursday, September 26th. This represents a $1.48 dividend on an annualized basis and a yield of 1.03%. The ex-dividend date of this dividend is Monday, September 9th. This is a boost from Steris's previous quarterly dividend of $0.34. View Steris' Dividend History.
How were Steris' earnings last quarter?
Steris PLC (NYSE:STE) released its quarterly earnings results on Monday, August, 5th. The medical equipment provider reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.11 by $0.12. The medical equipment provider earned $696.80 million during the quarter, compared to the consensus estimate of $674.12 million. Steris had a net margin of 11.22% and a return on equity of 13.80%. The business's revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.00 earnings per share. View Steris' Earnings History.
When is Steris' next earnings date?
What guidance has Steris issued on next quarter's earnings?
Steris updated its FY20 earnings guidance on Monday, August, 5th. The company provided EPS guidance of $5.38-5.53 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.40.
What price target have analysts set for STE?
4 equities research analysts have issued 12-month price targets for Steris' shares. Their predictions range from $138.00 to $157.00. On average, they anticipate Steris' stock price to reach $148.75 in the next year. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Price Targets for Steris.
What is the consensus analysts' recommendation for Steris?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steris in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Steris.
What are Wall Street analysts saying about Steris stock?
Here are some recent quotes from research analysts about Steris stock:
- 1. According to Zacks Investment Research, "Over the past year, STERIS has been outperforming its industry.The company’s favorable underlying market trends along with new product and service offerings buoy optimism. Growth in free cash flow reserve is indicative of the company’s strong cash balance. The company raising its constant currency organic revenue growth expectations for fiscal 2019 is indicative of brighter prospects. Last December, STERIS announced a restructuring plan that involved shutting down of two manufacturing units along with product rationalization. It has also made certain divestments and organizational changes, which are expected to better align with its operations. However, currently customer consolidation scenario is raising concern, which is likely to adversely impact STERIS. The competitive landscape and weak cost reduction initiatives of STERIS continue to be causes of concern for the company." (4/30/2019)
- 2. JMP Securities analysts commented, "We reiterate our Market Outperform rating on STERIS and price target of $135 following the release of F3Q19 results. STE announced quarterly results following Monday’s close, and will hold its call at 10 a.m. ET today; we will look for more color on guidance, as well as revenue and earnings drivers at that time. Our $135 price target is based on 23-24x our CY20 EPS estimate of $5.70. Our multiple reflects a slight discount to a group of mid-to-high single-digit growing, mid- cap MedTech peers." (2/14/2019)
Has Steris been receiving favorable news coverage?
Press coverage about STE stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Steris earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Steris.
Are investors shorting Steris?
Steris saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,560,200 shares, a decline of 19.8% from the July 31st total of 1,946,300 shares. Based on an average daily volume of 531,200 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.9% of the company's shares are short sold. View Steris' Current Options Chain.
Who are some of Steris' key competitors?
Some companies that are related to Steris include Edwards Lifesciences (EW), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), Align Technology (ALGN), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), Sientra (SIEN), Invacare (IVC), RTI Surgical (RTIX) and ConforMIS (CFMS).
What other stocks do shareholders of Steris own?
Who are Steris' key executives?
Steris' management team includes the folowing people:
- Mr. Walter M. Rosebrough Jr., CEO & Pres (Age 65)
- Mr. Michael J. Tokich, Sr. VP, CFO & Director (Age 50)
- Mr. Daniel A. Carestio, Chief Operating Officer (Age 46)
- Mr. John Adam Zangerle, Sr. VP, Gen. Counsel, Sec. & Director (Age 52)
- Dr. Adrian Vincent Coward, Sr. VP of Healthcare Specialty Services (Age 49)
Who are Steris' major shareholders?
Steris' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.69%), BlackRock Inc. (10.69%), Vanguard Group Inc. (9.31%), Janus Henderson Group PLC (7.68%), WCM Investment Management LLC (3.09%) and Invesco Ltd. (1.35%). Company insiders that own Steris stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard Martin Steeves, Sudhir K Pahwa, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Institutional Ownership Trends for Steris.
Which major investors are selling Steris stock?
STE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., Westfield Capital Management Co. LP, RE Advisers Corp, Bessemer Group Inc., Congress Asset Management Co. MA, Bank of America Corp DE and Russell Investments Group Ltd.. Company insiders that have sold Steris company stock in the last year include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard Martin Steeves, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Insider Buying and Selling for Steris.
Which major investors are buying Steris stock?
STE stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., BlackRock Inc., JPMorgan Chase & Co., Thoroughbred Financial Services LLC, Nuveen Asset Management LLC, TimesSquare Capital Management LLC and Allianz Asset Management GmbH. View Insider Buying and Selling for Steris.
How do I buy shares of Steris?
Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Steris' stock price today?
One share of STE stock can currently be purchased for approximately $144.12.
How big of a company is Steris?
Steris has a market capitalization of $12.21 billion and generates $2.78 billion in revenue each year. The medical equipment provider earns $304.05 million in net income (profit) each year or $4.89 on an earnings per share basis. Steris employs 12,000 workers across the globe.View Additional Information About Steris.
What is Steris' official website?
How can I contact Steris?
Steris' mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at 353-1232-2000 or via email at [email protected]
MarketBeat Community Rating for Steris (NYSE STE)
MarketBeat's community ratings are surveys of what our community members think about Steris and other stocks. Vote "Outperform" if you believe STE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STE will underperform the S&P 500 over the long term. You may vote once every thirty days.
